FierceBiotechOriginal article
{"a":[{"_":"Kolon TissueGene shrinks workforce after pivotal osteoarthritis trial miss","$":{"href":"/biotech/kolon-tissuegene-shrinks-workforce-after-pivotal-osteoarthritis-trial-miss","hreflang":"en"}}]}
Phase 3negativeNegative
AI Analysis
Summary
Kolon TissueGene failed its Phase 3 pivotal trial for a knee osteoarthritis treatment, prompting the company to lay off 37 employees at its Maryland headquarters. The CEO characterized the trial failure as causing significant disappointment and concern.
Clinical Trial Data
Phase
3
Primary Endpoint
Not Met
Outcome Details
Phase 3 knee osteoarthritis trial failure
Importance:7/10
Sentiment:
-0.90
phase_3_failureosteoarthritislayoffsclinical_trial
Read the original article
Published by FierceBiotech on August 18, 2026 3:44 PM